5 / 5
Page 28
conference
series
.com
Volume 7, Issue 11 (Suppl)
Med Chem (Los Angeles), an open access journal
ISSN: 2161-0444
MedChem & TDD 2017
December 06-08, 2017
December 06-08, 2017 Dallas, USA
18
th
International Conference on
Medicinal Chemistry & Targeted Drug Delivery
Preclinical researches on novel sugar dendritic Gd-DTPAMRI contrast agents and IER5/Cdc25B tageted
phospha sugar antitumor agents to innovate in cancer therapy
I
nnovative and strategic materials against tumor cells to decrease sharply the number of dead people by tumors are desired
eagerly. To innovate in medical technologies of diagnosis and cure for various kinds of tumors by novel medicinal materials,
i.e., sugar dendritic Gd-DTPA complex MRI contrast agent (DEN-OH) and IER5/Cdc25B targeted novel phospha sugar
antitumor agents (TBMPP) were prepared and evaluated
in vitro
and
in vivo
methods, and then these novel medicinal materials
were revealed preclinically to have excellent characters against tumor cells.
Biography
Mitsuji Yamashita has completed his PhD from Nagoya University, Japan, and Postdoctoral studies from Toyota Science and Chemistry Research Center, Japan,
and Iowa State University, USA, as well as a Visiting Professor of University of Massachusetts, USA, and a Visiting Researcher of Oxford University, UK. He was a
Professor of Shizuoka University, Japan, and he is now a Professor, Emeritus. He has published more than 180 papers and patents.
myama44@yahoo.co.jpMitsuji Yamashita
Shizuoka University, Japan
Mitsuji Yamashita, Med Chem (Los Angeles) 2017, 7:11 (Suppl)
DOI: 10.4172/2161-0444-C1-035